Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Sapanisertib + Bevacizumab for Glioblastoma
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is studying the side effects and best dose of the TORC1/2 inhibitor MLN0128 when given in combination with bevacizumab in treating patients with glioblastoma or other solid tumors.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service